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Abstract
The brain-derived neurotrophic factor (BDNF) has been suggested to play a pivotal role in the aetiology of
affective disorders. In order to further clarify the impact of BDNF gene variation on major depression
as well as antidepressant treatment response, association of three BDNF polymorphisms [rs7103411,
Val66Met (rs6265) and rs7124442] with major depression and antidepressant treatment response was
investigated in an overall sample of 268 German patients with major depression and 424 healthy controls.
False discovery rate (FDR) was applied to control for multiple testing. Additionally, ten markers in BDNF
were tested for association with citalopram outcome in the STAR*D sample. While BDNF was not as-
sociated with major depression as a categorical diagnosis, the BDNF rs7124442 TT genotype was signifi-
cantly related to worse treatment outcome over 6 wk in major depression (p=0.01) particularly in anxious
depression (p=0.003) in the German sample. However, BDNF rs7103411 and rs6265 similarly predicted
worse treatment response over 6 wk in clinical subtypes of depression such as melancholic depression
only (rs7103411 : TT<CC, p=0.003 ; rs6265 : GG<AA, p=0.001). All SNPs had main effects on anti-
depressant treatment response in ANOVA models when the remaining SNPs were considered as covari-
ates. The STAR*D analyses did not yield significant results at any of the ten BDNFmarkers. Our results do
not support an association between genetic variation in BDNF and antidepressant treatment response or
remission. Post-hoc analyses provide some preliminary support for a potential minor role of genetic vari-
ation in BDNF and antidepressant treatment outcome in the context of melancholic depression.
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Introduction
The brain-derived neurotrophic factor (BDNF) has at-
tracted much research interest with respect to its role
in the pathogenesis of affective disorders. BDNF, a
member of the neurotrophin superfamily, is cru-
cially involved in neuronal growth and in activity-
dependent neuronal plasticity (Duman, 1999). Given
the synaptic plasticity hypothesis of mood disorders,
BDNF has been suggested to play a pivotal role in the
aetiology of affective disorders as well as in the me-
diation of antidepressant treatment response (Green
& Craddock, 2003). For instance, Chen et al. (2001)
reported increased BDNF immunoreactivity in post-
mortem brains of patients under antidepressant medi-
cation, while depressive states in animal models have
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been found to be associated with reduced BDNF levels
in the brain, reversible by central administration of
BDNF (Nibuya et al. 1995 ; Shirayama et al. 2002;
Siuciak et al. 1997 ; Smith et al. 1995). Furthermore, ex-
pression of BDNF has been shown to be modified by
antidepressant treatment (Saarelainen et al. 2003).
The BDNF gene, located on chromosome 11p14
(MIM113505), encodes a precursor peptide (proBDNF),
which is subsequently cleaved into its mature form
(Seidah et al. 1996). A functional non-synonymous
single nucleotide polymorphism (SNP) causing an
amino-acid substitution of valine to methionine has
been identified in codon 66 (Val66Met, rs6265) (Egan
et al. 2003 ; Ventriglia et al. 2002).
In major depressive disorder (MDD), two Chinese
studies failed to detect an effect of BDNF variation in
relatively small samples of patients (Tsai et al. 2003:
n=152; Hong et al. 2003 : n=84). However, a signifi-
cant association of a three-locus BDNF haplotype
[rs988748, rs6265, (GT)n] was reported in a large case-
control study analysing two independent samples of
465 and 312 patients with MDD (Schumacher et al.
2005). The BDNF 66Met allele was observed to be
associated with harm avoidance as well as comorbid
anxiety disorders and major depression (Jiang et al.
2005), major depression in Mexican-Americans
(Ribeiro et al. 2007), geriatric depression (Hwang et al.
2006) and psychotic features and suicidal behaviour in
Japanese patients with MDD (Iga et al. 2007).
Association reports of the BDNF Val66Met poly-
morphism with four dimensions of neuroticism (de-
pression, self-consciousness, anxiety, vulnerability)
(Sen et al. 2003) as well as anxiety- and depression-
related traits (Lang et al. 2005) further support a
potential role of BDNF gene variation in the patho-
genesis of major depression. However, a recent meta-
analysis on genetic association studies of BDNF in
depression did not reveal a major role of BDNF
variation in major depression (Chen et al. 2008).
Two studies so far have investigated the impact of
the BDNF Val66Met polymorphism on antidepressant
treatment response : a significantly beneficial effect of
the Met allele on treatment response to citalopram was
observed in a sample of Korean patients with MDD
(Choi et al. 2006 ; n=83), while a Taiwanese study
reported a trend towards association of the hetero-
zygous Val66Met genotype with improved 4-wk fluox-
etine antidepressant response (Tsai et al. 2003, n=110).
However, there was no influence of BDNF Val66Met
genotype on treatment-resistant depression as a categ-
orical phenotype (Anttila et al. 2007).
Given these inconsistent findings available to date,
we attempted to re-evaluate the role of BDNF gene
variation in the aetiology of depression and in anti-
depressant treatment response investigating a set of
three SNPs including the functional Val66Met poly-
morphism (rs6265), rs7124442, which has been shown
to be functionally related to BDNF plasma levels in
eating-disorder subjects (Mercader et al. 2007), as well
as an intronic SNP rs7103411.
Material and methods
Sample
A sample of 268 unrelated Caucasian patients with a
current major depression (mean age 49.7¡15.4 yr ; 154
females, 114 males) admitted for in-patient treatment
was consecutively recruited at the Department of
Psychiatry, University of Muenster, Germany, be-
tween 2004 and 2006. For pharmacogenetic analyses,
only patients with a HAMD admission scoreo10 and
a treatment cycle of at least 6 wk from baseline were
considered, leaving a sample of n=256 patients with
major depression (mean age 50.4¡14.9 yr ; 145 fe-
males, 111 males). The mean HAMD score at ad-
mission was 23.1¡7.3 and at discharge it was 6.0¡5.0,
without showing any differences between gender and
diagnostic subtypes of depression. Patients with schi-
zoaffective disorders, bipolar disorder or comorbid
substance abuse disorders, mental retardation, preg-
nancy and neurological, neurodegenerative disorders
or other clinically unstable medical illnesses impair-
ing psychiatric evaluation were not included in this
analysis. In order to minimize the risk of ethnic strati-
fication, Caucasian descent was ascertained by Cauca-
sian background of both parents. The present sample
has already been described in published genetic or
pharmacogenetic studies targeting other gene systems
(Baune et al. 2008a, b ; Domschke et al. 2008a, b).
A control group of similar age and gender to the
cases consisted of 424 [mean age 52.7¡7.2 yr ; 214 fe-
males (mean age 52.1¡6.9 yr) ; 210 males (mean age
52.5¡7.8 yr)] healthy subjects of Caucasian German
descent, where the presence of current clinically rel-
evant depressive symptoms was excluded using the
Centre for Epidemiological Studies Depression Scale
(CES-D; Radloff, 1977).
Approval of the ethics committee of the University
of Muenster, Muenster, Germany, and written inform-
ed consent from all subjects were obtained.
We extended our study to include samples from
the Sequenced Treatment Alternatives to Relieve
Depression study (STAR*D). This sample is de-
scribed in detail in McMahon et al. (2006). In brief,
1953 outpatients (out of 4041) provided DNA for
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pharmacogenetic studies. All patients were treated
with citalopram at ‘level 1’ and were followed pro-
spectively for up to 14 wk. Bi-weekly follow-up visits
included assessments for severity and tolerability.
Assessment
Patients’ diagnoses considering major depression and
melancholic depression were ascertained by the use of
a structured clinical interview (SCID-I) according to
DSM-IV criteria. Anxious depression at admission was
as defined recently by Fava et al. (2008). A combined
anxiety/somatization factor o7 on the HAMD21 scale
was regarded as a criterion for anxious depression
(n=81 in the pharmacoresponse sample). Clinical
course of depression was assessed using the Hamilton
Depression (HAMD21) scale, the Clinical Global Im-
pression (CGI) scale and the Global Assessment of
Functioning (GAF) scale. While scores on the HAMD21
were obtained on a weekly basis, CGI and GAF scores
were obtained at admission and discharge only.
Adverse drug effects were monitored clinically but
were not systematically assessed using standardized
scales.
In the STAR*D sample, participants were required
to have a HAMD score ofo14 to enter the study. The
primary outcome measure for pharmacogenetics stu-
dies was the 16-item Quick Inventory for Depressive
Symptomatology – Clinician-rated version (QIDS-C16)
taken at each visit.
Response
In the German sample, clinical response to treatment
was measured by the relative intra-individual changes
of HAMD21 scores over the 6-wk study period as pre-
viously published (Baune et al. 2008a).
The phenotype definitions for the STAR*D sample
included remission and response as categorical vari-
ables and change in QIDS-C16 from baseline to end-
point as a continuous trait. To be included in the
analyses, participants needed to complete at least 6 wk
treatment and be able to tolerate citalopram. Those
who had at least a 50% improvement in QIDS-C16
score were considered responders and those who
achieved a score of f5 at endpoint were considered
remitters. Additional details can be found inMcMahon
et al. (2006).
Medication
Patients were treated in a naturalistic setting with a
variety of antidepressant medications [mirtazapine
(n=28, 10.9%), citalopram/escitalopram (n=38,
14.8%), venlafaxine (n=45, 17.6%), mirtazapine+
citalopram/escitalopram (n=38, 14.8%), mirtaza-
pine+venlafaxine (n=63, 24.6%), other (TCA, MAO
inhibitors (MAOIs), lithium; n=44, 17.2%)]. As co-
medication atypical antipsychotics (quetiapine, olan-
zapine, risperidone ; n=121, 47.3%) as well as mood
stabilizers (lithium, valproic acid ; n=60, 23.4%) were
used in addition to antidepressant treatment. Benzo-
diazepines were used in three cases only. None of the
included patients had received electroconvulsive
therapy within the 6 months preceding the present
investigation.
Genotyping
In the German sample, genotyping of rs7103411
(position: chr11:27,656,701) rs6265 (position: chr11:27,
636,492) and rs7124442 (position: chr11:27,633,617)
was carried out following published protocols apply-
ing the multiplex genotyping assay iPLEXTM for use
with the MassARRAY platform (Oeth et al. 2007),
yielding a genotyping completion rate of 93.7–96.6%
for all included patients and controls. While two
genotyping failures occurred in the overall depression
sample concerning each SNP (rs7103411/rs6265/
rs7124442, n=266), genotyping failures in the control
group resulted in a genotype availability of n=415
for rs7103411, n=415 for rs6265, and n=410 for
rs7124442. Genotypes were determined by investi-
gators blinded for clinical diagnoses.
In the STAR*D sample, ten SNPs in BDNF were
tested as a part of a larger list of 768 markers in 68
genes. The markers tested were : rs1519479, rs2203877,
rs1519480, rs6265 (Val66Met), rs11030104, rs12273363,
rs7931247, rs1491850, rs7119334 and rs10742184. These
SNPs were genotyped at Illumina Inc. (USA) with a
99% success rate.
Statistical analysis
The categorical association analysis of allele and geno-
type distribution across patients with major depres-
sion (n=268) and age- and gender-matched healthy
controls was performed by means of Armitage’s trend
test as provided by the DeFinetti program available
as an online source (http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl ; T. F. Wienker & T. M. Strom).
Comparisons of HAMD, CGI and GAF baseline
scores across genotype groups were carried out with
one-way ANOVA (>2 categories). The pharmaco-
genetic investigation of BDNF variant effects on
HAMD change scores over 6 wk antidepressant treat-
ment was performed using an ANOVA with repeated
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measures (genotype as fixed factor and time-point as
repeated measure), and number of covariates (see
below) (Table 1). False discovery rate (FDR; Benjamini
& Hochberg, 1995) was applied to control for multiple
testing and prevent Type I error. FDR was applied in
two different ways. First, FDR was calculated for the
number of hypotheses tested in the present study.
The resulting FDR (labelled as ‘within-sample FDR’)
has a corrected p value of f0.014. Second, FDR was
calculated based on the current BDNF analysis plus
pharmacogenetic analyses of other neurotransmitter
systems in this sample of MDD patients as previously
published by our group (Baune et al. 2008b ; Domschke
et al. 2008a, b). The resulting FDR is labelled ‘between-
samples FDR’ and shows a corrected p value of
f0.01.
The ANOVA analyses were stratified for gender,
anxious and melancholic depression. Covariates (e.g.
age, gender, duration of depressive illness, lifetime
number of depressive episodes, number of hospital-
izations due to depression, class of antidepressant, i.e.
SSRIs, SNRA, NaSSRA, TCAs, MAOIs, polypharmacy,
Table 1. Overall reduction of % HAMD scores across BDNF rs7103411, rs6265, rs7124442 genotypes in the pharmacogenetic
sample of patients with major depression (n=254) stratified for gender, anxious and melancholic depression
BDNF genotypes
Major depression (% HAMD reduction)
p valuea,bMean¡S.E. Mean¡S.E. Mean¡S.E.
Rs7103411
HAMD change weeks 2–6c,e CC (n=14) CT (n=85) TT (n=155)
MDD (n=254) x68.0¡18.2 x33.0¡7.0 x20.0¡5.2 0.034
Female (n=144)d x50.1¡25.3 x23.0¡11.0 x23.5¡6.8 0.082
Male (n=110)d x75.4¡26.5 x40.1¡9.0 x17.0¡8.3 0.009
Anxious depression (n=81) x93.0¡28.3 x52.4¡10.1 x22.2¡7.9 0.005
Melancholic depression (n=95) x97.4¡28.8 x52.7¡10.1 x1.1¡10.5 0.003
Rs6265
HAMD change weeks 2–6c,e AA (n=11) AG (n=80) GG (n=163)
MDD (n=254) x16.0¡20.0 x10.6¡7.4 x35.1¡5.0 0.411
Female (n=144)d x32.7¡28.5 x16.6¡10.9 x27.8¡6.5 0.88
Male (n=110)d x2.9¡27.2 x8.6¡9.9 x42.7¡7.7 0.23
Anxious depression (n=81) x33.6¡29.6 x6.9¡11.3 x53.2¡7.1 0.27
Melancholic depression (n=95) 55.7¡30.5 2.7¡10.9 x58.5¡10.1 0.001
Rs7124442
HAMD change weeks 2–6c,e CC (n=31) CT (n=97) TT (n=126)
MDD (n=254) x44.4¡6.6 x23.4¡3.7 x24.7¡3.3 0.01
Female (n=144)d x47.2¡9.4 x23.1¡5.3 x21.1¡4.4 0.06
Male (n=110)d x41.1¡9.1 x23.1¡5.1 x30.7¡4.9 0.34
Anxious depression (n=81) x66.1¡12.1 x37.2¡6.6 x33.6¡5.5 0.003
Melancholic depression (n=95) x20.9¡14.1 x38.5¡5.5 x22.3¡4.8 0.70
HAMD, Hamilton Depression Rating Scale ; MDD, major depressive disorder.
p value=ANOVA with repeated measures [covariates : age, gender, polypharmacy (treatment with various antidepressants)
and treatment with antidepressants+atypical antipsychotics, HAMD score at admission] for the comparison of HAMD change
score between homozygous genotypes.
Bold and italics=significant p value at significance after false discovery rate (FDR) correction for multiple hypotheses testing.
a In this analysis : FDR p value cut-off=0.014 ; b FDR p value cut-off=0.01, obtained from the combination of this and previous
analyses as published by our group (Baune et al. 2008b ; Domschke et al. 2008a, b).
c p values from ANOVAmodels with covariates age, gender, polypharmacy (treatment with various antidepressants), treatment
with antidepressants+atypical antipsychotics, HAMD score at admission.
d Covariates : age, polypharmacy (treatment with various antidepressants), treatment with antidepressants+atypical
antipsychotics, HAMD score at admission.
e Intra-individual relative change scores of the HAMD21 scale between weeks 2 and 6 : multivariable ANOVA [covariates : age,
gender polypharmacy (treatment with various antidepressants), treatment with antidepressants+atypical antipsychotics,
HAMD score at admission] with repeated measures independent of change in week 1.
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treatment with antidepressants+atypical antipsycho-
tics, antidepressants+mood stabilizer or family his-
tory of mental disorders) were included in these
multivariable ANOVA models, if they showed an im-
pact on treatment response over 6 wk. In order to test
whether the three investigated SNPs affect treatment
response independently of each other, the BDNF
SNP of interest was entered as a fixed factor while the
respective other two BDNF SNPs were included as
covariates in the ANOVA models.
In addition, we performed separate multiple
ANOVAs (for included covariates see above; applying
FDR cut-off of pf0.014) to obtain results on the
weekly intra-individual HAMD change scores across
genotype groups. In addition, separate ANOVAs were
performed to investigate if the effects of the BDNF
genotypes on treatment response were mediated
through covariates (dummy variables) such as class
of antidepressant, i.e. SSRIs, SNRA, NaSSRA, TCAs,
MAOIs (SSRIs vs. TCAs, MAOIs), treatment with anti-
depressants+atypical antipsychotics (antidepressant
alone vs. antidepressant+atypical antipsychotics)
or antidepressants+mood stabilizer (antidepressant
alone vs. antidepressant+mood stabilizer). With these
parameters, for continuous measurements, our sample
had a high power (80%) to detect a difference of at
least 3.6% change on the HAMD scale between two
genotypes. Hardy–Weinberg equilibrium was exam-
ined using the DeFinetti program
For haplotype analyses, the most frequent ‘TGT’
haplotype (rs7103411/rs6265/rs7124442) (46.9%, de-
termined by means of Haploview 4.0) containing the
associated rs7124442 T allele was analysed against the
remaining haplotypes for association with depression
and for pharmacoresponse over 6 wk antidepressant
treatment.
The association analyses in STAR*D were per-
formed using PLINK. To account for potential racial
stratification, given the racial heterogeneity of STAR*D
participants that could cause an inflation of association
results, we used genomic control. Post-hoc tests in-
cluded stratification based on gender and depression
subtype (anxious and melancholic).
Results
In the German sample, the distribution of rs7103411,
rs6265 and rs7124442 genotypes did not signifi-
cantly differ from the expected numbers calculated on
the basis of observed allele frequencies according
to the Hardy–Weinberg equilibrium for the overall
patient sample (rs7103411: p=0.75 ; rs6265 : p=0.95 ;
rs7124442: p=0.14), the pharmacogenetic sample
(rs7103411: p=0.59 ; rs6265 : p=0.77 ; rs7124442:
p=0.074) as well as for the control sample (rs7103411:
p=0.31 ; rs6265 : p=0.24 ; rs7124442: p=0.48). Linkage
disequilibrium between the three SNPs was mod-
erately high between rs6265 and rs7103411 (D’=
0.976, r2=0.8252) and low between SNPs rs6265
and rs7124442 (D’=x0.973, r2=0.0948) and SNPs
rs7103411 and rs7124442 (D’=x0.937, r2=0.1).
None of the three BDNF SNPs was associated with
severity of depression as measured by HAMD score at
baseline, number of lifetime episodes of depression,
suicide attempts and duration of illness in years.
Categorical association results in the German sample
No association of any of the three investigated BDNF
polymorphisms with major depression was observed
(rs7103411: p=0.79 ; rs6265 : p=0.51 ; rs7124442:
p=0.16) in the samples of 268 patients with major
depression and 424 controls. The case and control
samples showed similar distributions for age and
gender. A diagnostic subtyping into anxious de-
pression (n=81) and melancholic depression (n=95)
also revealed no association with any of the BDNF
SNPs. No significant allele frequency differences be-
tween cases and controls were observed for any of the
three SNPs. In addition, dichotomous haplotype
analyses for the rs7103411/rs6265/rs7124442 TGT
haplotype (vs. rest) showed no associations with de-
pression or diagnostic subtypes.
Pharmacogenetic results in the German sample
Within the pharmacogenetic sample comprising 254
patients (admission HAMD score o10) with major
depression, the subsamples stratified for gender,
anxious depression and melancholic depression did
not significantly differ for age, education, marital
status or comorbidity with anxious depression. Since
treatment response over 6 wk (expressed through the
overall HAMD % change) was influenced by gender,
age, polypharmacy (treatment with various anti-
depressants) and treatment with antidepressants+
atypical antipsychotics, these variables were con-
sidered as covariates in multivariate ANOVA pro-
cedures. Conversely, treatment response over 6 wk
was not influenced by duration of depressive illness,
lifetime number of depressive episodes, number of
hospitalizations, class of antidepressant (i.e. SSRIs,
SNRAs, NaSSRAs, TCAs, MAOIs), antidepressants+
mood stabilizer or family history of mental disorders
(data not shown).
Table 1 presents results from ANOVA and the
BDNF SNP of interest as fixed factor (covariates age,
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gender, polypharmacy and treatment with anti-
depressants combined with atypical antipsychotics,
remaining two BDNF SNPs) with repeated measures
for the intra-individual % HAMD reduction over the
course of 6 wk antidepressant treatment across geno-
types of the three investigated BDNF SNPs. The
TT genotype of BDNF rs7124442 was significantly re-
lated to worse treatment outcome over 6 wk in MDD
(p=0.01), particularly in anxious depression (p=
0.003). The other two investigated BDNF SNPs simi-
larly predicted worse treatment response over 6 wk in
the melancholic subtype of depression (rs7103411:
TT<CC genotype, p=0.003 ; rs6265 : GG<AA geno-
type, p=0.001) and partly in anxious depression
(rs7103411: TT<CC genotype, p=0.005) and male
gender (rs7103411: TT<CC genotype, p=0.009) (see
Table 1). However, analyses across all three genotypes
or applying a recessive model did not reveal signifi-
cant results. All of these results remain significant after
applying the within-sample FDR (cut-off pf0.014)
and between analyses FDR (cut-off pf0.01).
Furthermore, haplotype analyses for the rs7103411/
rs6265/rs7124442 TGT haplotype containing the as-
sociated rs7124442 T allele (vs. rest) showed an as-
sociation with overall worse treatment response
over 6 wk in MDD (HAMD reduction x22.9% vs.
x39.4%, p=0.005), in anxious depression (HAMD
reduction x31.5% vs. x62.8%, p=0.004) and in fe-
male patients (HAMD reductionx25.7% vs.x37.1%,
p=0.01).
Regarding the course of BDNF gene variation im-
pacting on treatment response (HAMD reduction),
BDNF rs7124442 (comparison of homozygous geno-
types CC vs. TT) showed an early effect after 2 wk
antidepressant treatment which was maintained up
to week 6 in the overall group of patients with major
depression (HAMD at week 2: x28.8% vs. x11.0%,
p=0.027 ; HAMD at week 3:x41.2% vs.x17.1%, p=
0.007 ; HAMD at week 4: x44.9% vs. x28.9.0%,
p=0.12 ; HAMD at week 5: x57.1% vs. x30.2.0%,
p=0.009 ; HAMD at week 6:x59.1% vs.x37.1%, p=
0.049) as well as in the subgroup of anxious depression
showing early effects after 3 wk treatment (HAMD
at week 2: x45.6% vs. x19.8%, p=0.11 ; HAMD at
week 3: x67.8% vs. x22.5%, p=0.012; HAMD at
week 4: x73.4% vs. x34.9%, p=0.027; HAMD
at week 5: x90.3% vs. x38.5%, p=0.008; HAMD at
week 6: x98.4% vs. x44.8%, p=0.004). When apply-
ing the within-sample FDR cut-off p value (0.014), the
results for pharmacoresponse in the overall MDD
sample remain significant for weeks 3 and 5, whereas
the anxious depression subgroup shows significant
results for weeks 3, 5 and 6.
BDNF-related pharmacoresponse specific for type of
antidepressant treatment in the German sample
When investigating patients with major depression
stratified for type of antidepressant medication, a sig-
nificantly negative influence of the BDNF rs7124442
TT genotype on treatment response was observed for
SSRI antidepressants over 6 wk treatment as opposed
to the CC genotype (HAMD reduction for TT vs. CC
genotype: x22.6% vs. x59.8%, p=0.002). The effect
was first visible after 3 wk antidepressant treatment
(mean difference between CC and TT genotypes :
x38.1%, p=0.002) and became most prominent after
5 and 6 wk treatment (week 5: mean difference be-
tween CC and TT genotypesx47.4%, p=0.002; week
6: mean difference between CC and TT genotypes
x48.4%, p=0.007). These p values are lower than
the FDR cut-off of pf0.014 and therefore remain stat-
istically significant. This could not be observed for
any other class of antidepressant. Moreover, BDNF
rs7124442 did not have any influence on treat-
ment response under polypharmacy, treatment with
antidepressants+atypical antipsychotics or anti-
depressants+mood stabilizers.
Applying multivariable ANOVA (covariates : age,
gender, class of antidepressants) for the influence of
the three BDNF SNPs on GAF and CGI change scores
between admission and discharge, no significant
pharmacogenetic treatment effects for either of the
global scales was detected in patients with MDD or
anxious depression.
Pharmacogenetic results in STAR*D sample
The STAR*D analyses including remission, response
and change in QIDS-C16 score did not yield any sig-
nificant results at any of the ten markers reported
in the present study. Post-hoc tests, stratifying on de-
pression subtype showed no associations after correc-
tion for multiple testing.
Discussion
Despite no overall association finding of BDNF var-
iants with major depression, the present study in-
vestigating BDNF gene variants in major depression
supports a potential role of BDNF rs7124442 as well as
a rs7103411/rs6265/rs7124442 haplotype containing
the associated rs7124442 T allele in treatment response
to antidepressants in the German sample. BDNF
rs7124442 has previously been analysed with respect
to Alzheimer’s disease (Huang et al. 2007), but has not
been examined in depression to the best of our
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knowledge. BDNF rs7124442 is located in exon VIII
after the polyadenylation site in the 3’ untranslated
region of the BDNF gene (LocusLink. National Center
for Biotechnology Information : http://www.ncbi.
nih.gov). Given the converging evidence for a reduced
BDNF state in depression (see above), the rs7124442 T
allele associated with impaired treatment response to
antidepressants might confer a decreased BDNF ac-
tivity or expression by as yet unknown mechanisms of
alternative splicing for example. However, this hy-
pothesis has to be considered speculative at this stage,
since no molecular genetic functional data on this
polymorphism are yet available and Mercader and
colleagues found an increase in plasma BDNF levels
associated with the rs7124442 T allele (Mercader et al.
2007).
The observed potential impact of BDNF rs7124442
on antidepressant treatment response particularly
under SSRI treatment fits well with studies in the rat
model, where administration of SSRIs has been re-
ported to significantly increase BDNF levels (Altar
et al. 2003 ; Neeper et al. 1996). The interaction between
serotonin and BDNF has been described as being re-
ciprocal, with BDNF on the one hand promoting de-
velopment and function of serotonergic neurons
and serotonin as amplified by SSRIs on the other hand
increasing BDNF transcription via cAMP responsive
element binding protein (CREB) phosphorylation (as
reviewed by Martinowich & Lu, 2008).
Furthermore, the present association of BDNF
rs7124442 seems to originate solely from the female
subgroup of patients. This is in line with previous ob-
servations of gender-specific pharmacogenetic effects
such as in MAOA (Domschke et al. 2008b). Major de-
pression is approximately twice as frequent in women
as in men (Weissman et al. 1993) with a significantly
higher heritability in women (42%) than in men (29%)
(Jansson et al. 2004; Kendler et al. 2006), which sug-
gests a sexually dimorphic pattern of genetic suscep-
tibility to the disorder potentially in part being
conferred by BDNF gene variation.
However, apart from a potential effect in the sub-
group of melancholic and partly anxious depression
we did not detect any effect of the BDNF Val66Met
polymorphism or rs7103411 on overall antidepressant
treatment response in patients with major depres-
sion.
This is in line with the failure to observe any as-
sociation of any of the ten investigated BDNF markers
in the STAR*D sample including BDNF Val66Met
with citalopram treatment. Although a false-positive
finding in the German sample cannot be ruled out,
SNP rs7124442 was not genotyped in STAR*D.
Furthermore, none of the markers included are in sig-
nificant linkage disequilibrium with rs7124442, there-
fore Type II error cannot be excluded either.
The following limitations have to be considered
while interpreting the present results. In the German
sample, patients were recruited in a naturalistic setting
allowing for a large sample size ; however, this implies
treatment with a variety of antidepressants, no stan-
dardized dosage regime and no standardized control
of plasma drug levels. Thus, treatment compliance
could only be controlled for by routine nurse ob-
servations lacking objective measures of compliance,
which has to be considered a possible major con-
founding factor. Furthermore, none of the patients
was drug naive with respect to antidepressant
medication ; however, no detailed data on the type of
antidepressant pre-medication was available. Anti-
depressant treatment prior to the present investigation
might have influenced the presently evaluated treat-
ment response which could not be controlled for in
detail. In addition, since a priori only patients with a
treatment cycle of at least 6 wk from baseline were
included in the present study, no drop-outs due to
non-response could be accounted for. Moreover, co-
morbidity with personality disorders could not
be controlled for, which might have confounded the
present pharmacogenetic finding. Furthermore, the
relatively small sample sizes of patients in the diag-
nostic subgroups (stratification for gender, melan-
cholic and anxious depression, subgroups receiving
a single antidepressant medication, three-way inter-
actions) might have increased the risk for a false-
negative as well as a false-positive result. Thus, the
present observations regarding depression subtype or
pharmacotherapy type cannot be conclusively evalu-
ated and have to be considered as exploratory results.
Since a number of tests were carried out here, Type I
error might have occurred in the pharmacogenetic
analyses despite the introduction of FDR-corrected
p values for this study and in comparison to other
pharmacogenetic studies published by our group
(Baune et al. 2008b ; Domschke et al. 2008a, b). Finally,
grouping of genotypes underlying the present results
has to be considered arbitrarily, since with the excep-
tion of BDNF Val66Met (rs6265) no functional data on
the selected BDNF variants are currently available.
In summary, we did not find an association between
genetic variation in BDNF and antidepressant treat-
ment response and remission. Post-hoc analyses pro-
vide some preliminary support for a potential minor
role of genetic variation in BDNF and antidepressant
treatment outcome in the context of melancholic de-
pression.
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